Linked Life Data

9157295

Source:http://linkedlifedata.com/resource/pubmed/id/9157295

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
1997-5-21
pubmed:abstractText
Many tumours depend on the formation of an own vascular system to support progressive tumour growth. This is accomplished through induction of vessel growth from pre-existing vessels, a process called neo-angiogenesis. Therefore, inhibiting neo-angiogenesis and modulating tumour perfusion constitute attractive possibilities for tumour therapy, combined, of course, with treatment aimed at the tumour cells themselves. By now many angiogenesis inhibitors have been developed, but their use is mostly still experimental. They inhibit endothelial proliferation and migration (fumagillin derivates, angiostatin, suramin) or prevent proteolytic degeneration of the extracellular matrix by products of the tumour (metalloproteinase inhibitors). Improving tumour oxygenation and perfusion by carbogen inhalation and nicotinamide or vasoactive agents (flunarizine, verapamil, nicotinamide) enhances the effects of radiotherapy and improves delivery of chemotherapeutic agents to the tumour. Research is currently in progress into the efficacy of accelerated radiotherapy in combination with carbogen inhalation and administration of nicotinamide in tumours of the head and neck, bladder, bronchi and brain.
pubmed:language
dut
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0028-2162
pubmed:author
pubmed:issnType
Print
pubmed:day
22
pubmed:volume
141
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
364-8
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
[Vascularization and perfusion of tumors as target in cancer therapy].
pubmed:affiliation
Ziekenhuis Canisius-Wilhelmina, afd. Neurologie, Nijmegen.
pubmed:publicationType
Journal Article, English Abstract, Review, Research Support, Non-U.S. Gov't